Abstract: A system and method for vehicle health management is provided that gives improved flexibility and performance. The vehicle health management system and method utilizes a modular approach that divides the VHM system into logical sub-elements separated by defined interfaces. The modular approach allows new features and functionality to be more easily added to the VHM, improving the flexibility and performance of the system. The vehicle health management system includes a data service, a symptom detection service and a diagnostic service. The data service receives system data from a plurality of sources and formats the data and then delivers the formatted data to the symptom detection service. The symptom detection service analyzes the formatted data for symptoms of system failure. Those portions of data that are indicative of system failure are then passed to the diagnostic service. The diagnostic service examines those portions of data to determine any potential diagnoses.

Abstract: A system and method for vehicle health management is provided that gives improved flexibility and performance. The vehicle health management system and method utilizes a modular approach that divides the VHM system into logical sub-elements separated by defined interfaces. The modular approach allows new features and functionality to be more easily added to the VHM, improving the flexibility and performance of the system. The vehicle health management system includes a data service, a symptom detection service and a diagnostic service. The data service receives system data from a plurality of sources and formats the data and then delivers the formatted data to the symptom detection service. The symptom detection service analyzes the formatted data for symptoms of system failure. Those portions of data that are indicative of system failure are then passed to the diagnostic service. The diagnostic service examines those portions of data to determine any potential diagnoses.

Abstract: The A21 receptor extracelluar site and the A2 receptor extracellular site of adenosine analogues are structurally different and that binding orientations of adenosine or adenosine analogues are different at these sites and this may be used to determine their structure. Novel pyrimidine compounds are described.

Abstract: The invention relates to a compound, 1-methyl-9.beta.-D-ribofuranosyl-isoguanine, and to a process for the preparation thereof by isolation from natural sources. The compound has muscle relaxing, central nervous system, anti-inflammatory, anti-allergy and hypotensive activity.

Abstract: A process to produce 1-methyl isoquanosine, a compound of the formula ##STR1## is disclosed. Also disclosed is a novel intermediate in said process. The 1-methyl isoguanosine has been found to have pharmacological activity, e.g. anti-inflammatory activity and muscle relaxant activity.